Similar Papers

Paper Title
Journal
Date
Author
New targeted therapies in spondyloarthritis: what are the limits?
Daniel Wendling
Immunotherapy | VOL. 11
Daniel WendlingDaniel Wendling
04 Apr 2019
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
Philip Mease ... Oliver Fitzgerald
New England Journal of Medicine | VOL. 377
Philip Mease, et. al.Philip Mease ... Oliver Fitzgerald
19 Oct 2017
Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study.
Peter Nash ... Sujatha Menon
Rheumatology and Therapy | VOL. 7
Peter Nash, et. al.Peter Nash ... Sujatha Menon
06 Jun 2020
Conventional Synthetic Dmards in Psoriatic Arthritis: Changing Practice in Biologic Era; Real-Life Results from HURBIO-PsA Registry
Emre Bilgin ... Umut Kalyoncu
Acta Medica | VOL. -
Emre Bilgin, et. al.Emre Bilgin ... Umut Kalyoncu
16 Nov 2021
View more papers

More From: Immunotherapy

Paper Title
Journal
Date
Author
Proton pump inhibitors reduce nivolumab efficacy in unresectable advanced or recurrent gastric cancer.
Masahito Shibano ... Hiroyasu Kaneda
Immunotherapy | VOL. -
Masahito Shibano, et. al.Masahito Shibano ... Hiroyasu Kaneda
14 Apr 2025
A plain language summary of a review about omalizumab for people with chronic spontaneous urticaria
Thomas B Casale ... Marcus Maurer
Immunotherapy | VOL. -
Thomas B Casale, et. al.Thomas B Casale ... Marcus Maurer
07 Apr 2025
Real-world data of immune-related adverse events in lung cancer patients receiving immune-checkpoint inhibitors
Xiao Hu ... Susan K Parsons
Immunotherapy | VOL. -
Xiao Hu, et. al.Xiao Hu ... Susan K Parsons
04 Apr 2025
Effects of cannabinoids on immune checkpoint inhibitor response: CCTG pooled analysis of individual patient data
Courtney H Coschi ... Andrea S Fung
Immunotherapy | VOL. -
Courtney H Coschi, et. al.Courtney H Coschi ... Andrea S Fung
04 Apr 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.